Study of LTC004 Combine With Toripalimab in Patient With Solid Tumors Resistant to Immunotherapy

Summary

To evaluate the efficacy and safety of LTC004 in combination with Toripalimab in 10 patients with advanced solid tumors resistant to first-line immunotherapy, all eligible subjects will receive LTC004 on day 1 of Week 1 and day 1 of week 3. Beginning at week 5, all subjects will receive LTC004 in combination with Toripalimab regimen until disease progression, intolerance, informed withdrawal or up to 2 years of dosing, whichever occurred first.

Timeline

Start

2024-06-04

Primary completion

2026-03-31

Completion

2026-03-31

Drugs

Indications